Core Viewpoint - Abbott is set to announce its fourth-quarter 2025 financial results on January 22, 2026, before market opening, followed by a live webcast of the earnings conference call [1] Group 1: Financial Announcement - The financial results announcement will occur on January 22, 2026, before the market opens [1] - A live webcast of the earnings conference call will take place at 8 a.m. Central time (9 a.m. Eastern) [1] - The archived edition of the call will be available later that same day [1] Group 2: Company Overview - Abbott is a global healthcare leader with a focus on helping people live fully at all stages of life [2] - The company's portfolio includes technologies in diagnostics, medical devices, nutritionals, and branded generic medicines [2] - Abbott employs 114,000 colleagues and serves customers in over 160 countries [2]

TEL AVIV, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. The presentation will begin at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time). To access a live webcast of the presentation, visit Teva’s Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations. An archived version o ...

Key Takeaways U.S. military action of capturing Venezuela's leadership triggers a major geopolitical shock globally.Venezuela's oil impact is limited, as it produces about 1% of global supply and Chevron's exposure is small.Defense, cybersecurity tech & healthcare stocks stand to benefit from higher security spending and stability.The year 2026 has started in an unusually volatile way. The United States’ recent military action to capture Venezuela, home to the world’s largest proven oil reserves, has come a ...

Company Overview - Cencora Inc (NYSE:COR) is a significant player in the medical sector, focusing on specialty drugs and healthcare solutions [1][5] - The company's market capitalization is approximately $64.37 billion, indicating its substantial presence in the industry [4][5] Stock Performance - On January 5, 2026, Bank of America Securities adjusted its rating for Cencora to Neutral, with the stock priced at $332.12, reflecting a decrease of 1.99% or $6.75 for the day [1][5] - The stock has experienced a 52-week high of $377.54 and a low of $227.95, showcasing significant volatility [2] Market Trends - Wall Street analysts maintain a bullish outlook for Cencora, driven by the adoption of artificial intelligence and increased demand for specialty drugs [2][5] - The medical sector is transitioning from a defensive position to a growth engine, with artificial intelligence enhancing efficiency and precision in diagnostics and drug discovery [3] Trading Activity - Cencora's daily trading volume is 227,149 shares, with a trading range of $329.10 to $337.31, reflecting the dynamic nature of the market [4]

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Market update : Stocks are higher for the second session in a row. Energy is a big story on Monday, with oilfield services, refiners, and the two majors, Exxon Mobil and Chevron , rallying on the idea that they will be beneficiaries of the rebuilding of Venezuela's oil infrastructure following the events over the weekend. The financials a ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a growth stock that can live up to its true potential can be a tough task.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, the Zacks Growth Style Score (part of the Zacks Style ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

stocks they discuss. We make no representations or warranties regarding the advisability of investing in any particular securities or utilizing any specific investment strategies. Information is subject to change without notice. For information on use of our services, please see our Terms of Use. *Real-time prices by Nasdaq Last Sale. Real-time quote and/or trade prices are not sourced from all markets. Ownership data provided by LSEG and Estimate data provided by FactSet. IBD, IBD Digital, IBD Live, IBD We ...

Core Viewpoint - The stock market presents compelling opportunities as the US economy shows resilience, the AI boom continues, and equity rallies broaden beyond a few leading stocks, creating favorable conditions for stock selection heading into 2026 [1] Group 1: Zacks Rank and Stock Selection - The Zacks Rank is highlighted as an effective investment tool with a strong track record of identifying emerging leaders before they gain widespread recognition [2] - Three stocks are identified as top picks: Pagaya Technologies Ltd. (PGY), Eli Lilly (LLY), and Weatherford International (WFRD), all carrying a top Zacks Rank and backed by strong growth expectations and attractive valuations [3] Group 2: Eli Lilly (LLY) - Eli Lilly has shown exceptional performance due to the adoption of GLP-1 weight-loss therapies, experiencing a powerful stock advance towards the end of 2025 after a temporary pause [5][6] - The stock is currently rated Zacks Rank 1 (Strong Buy) with earnings estimates revised upward, trading at 32.2x forward earnings, and projected EPS growth of 41.4% annually over the next three to five years [6] - Technical analysis indicates a bullish setup, with a recent breakout above resistance levels suggesting potential for further gains [7] Group 3: Pagaya Technologies Ltd. (PGY) - Pagaya Technologies is positioned in the "buy now, pay later" (BNPL) space, previously highlighted for its strong growth projections and attractive valuation, with shares having more than tripled before a significant pullback [9][10] - The stock has returned to a Zacks Rank 1 (Strong Buy), trading at 6.5x forward earnings, with sales expected to grow by 28.4% this year and 19.2% next year, alongside a projected earnings growth of 274% [10] - Recent technical movements indicate a potential pivot point for renewed buying interest, suggesting favorable conditions for investors [11] Group 4: Weatherford International (WFRD) - Weatherford International's shares have risen sharply amid geopolitical developments affecting global energy markets, particularly following military actions in Venezuela [13] - The stock has maintained a top Zacks Rank and has shown signs of renewed leadership in the energy sector prior to recent events [14] - Technical analysis shows a decisive breakout from a bull flag pattern, reinforcing a bullish outlook for Weatherford and the broader energy sector [15] Group 5: Investment Considerations - Each of the highlighted stocks offers unique investment opportunities: Eli Lilly as a structural growth leader, Pagaya as a high-upside growth story, and Weatherford as a play on a resurgent energy cycle [16]